A newly published meta-analysis in JAMA Pediatrics challenges a widespread political talking point by demonstrating that bone density loss in transgender adolescents on puberty blockers is largely recovered once they transition to gender-affirming hormone therapy. Examining data across 10 distinct cohorts encompassing 751 transgender youth—comprising 427 individuals assigned male at birth and 324 assigned female at birth—European researchers evaluated key skeletal sites including the lumbar spine, total hip, and femoral neck to assess long-term impacts on bone health.
The study found that while puberty suppression temporarily slows down the accrual of bone mass, initiating hormone replacement therapy leads to a clear recovery. Researchers characterized the post-suppression outcome as “at most a modest and uncertain shortfall in catch-up rather than a demonstrated persistent deficit,” noting that although bone density scores remained numerically below baseline levels, they were “not consistently statistically different across skeletal sites.”
Speaking on the dynamic nature of skeletal growth during medical intervention, lead researcher Dr. Daniele Tienforti emphasized the temporary nature of the slowdown. “Our results suggest that puberty suppression temporarily slows bone accrual, but this is followed by a clear recovery after gender-affirming hormone therapy is initiated,” Dr. Tienforti noted. He further advised clinicians to view treatment holistically over time rather than evaluating bone health in isolation: “Rather than focusing on a single phase of treatment, I think it’s important to view skeletal development as a dynamic process that deserves ongoing attention throughout care.”
The findings carry significant weight given that approximately 40% to 60% of lifetime bone mass is acquired during adolescence, making bone mass accrual critical for long-term health and fracture prevention. Beyond puberty blockers, the study identified additional variables influencing bone density outcomes, including body mass index. While longer exposure to puberty blockers correlated with lower initial bone density scores, extended exposure to hormone replacement therapy subsequently improved lumbar spine density scores among adolescents assigned male at birth.
These findings directly counter claims raised in publications like the controversial British Cass Review, which cited bone density concerns as a key argument against prescribing puberty blockers to youth. Pushing back against exaggerated claims, the study’s authors summarized the broader medical evidence surrounding youth gender care: “In youth gender care, we have evidence that these medications effectively treat gender dysphoria, that young people continue these medications into adulthood, that their satisfaction with gender-affirming medical treatments is high, that their bone density recovers after puberty-pausing medications, and that their transgender identities persist.”
To optimize health outcomes, Dr. Tienforti recommended close monitoring of bone mineral density throughout a young person’s care journey, alongside routine recommendations such as adequate calcium and vitamin D intake and weight-bearing exercise. The study aligns with previous long-term research, including a 2023 Dutch study that tracked patients 10 years after stopping puberty blockers and similarly observed substantial recovery in bone mineral density.
Photo courtesy of Unsplash
